Publications by authors named "Charles Drake"

Claim this Profile
M
Metabolic Reprogramming of T Cells by Dual UCP2 and IL-17 Blockade Enhances Immunity Against Pancreatic Cancer.
Chuan-Teng Liu, Chun-Chieh Yeh, Tsai-Chen Wu, Chia-Hsin Lin, Yi-Ting Kuo, Charles Drake

Adv Sci (Weinh)· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer.
Fei Shen, Ryan Smith, Theresa McDevitt, Krista Menard, Shaozhou Tian, Charles G Drake

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer.
Casey R Ager, Aleksandar Obradovic, Patrick McCann, Matthew Chaimowitz, Alexander L E Wang, Charles G Drake

medRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.
Lisa N Chesner, Fanny Polesso, Julie N Graff, Jessica E Hawley, Alexis K Smith, Charles G Drake

Cancer Discov· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
Matthew C Dallos, Aleksandar Z Obradovic, Patrick McCann, Nivedita Chowdhury, Aditya Pratapa, Charles G Drake

Clin Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity.
Hong Yu, Hiroshi Nishio, Joseph Barbi, Marisa Mitchell-Flack, Paolo D A Vignali, Charles Drake

Elife· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity.
Hong Yu, Hiroshi Nishio, Joseph Barbi, Marisa Mitchell-Flack, Paolo D A Vignali, Charles G Drake

bioRxiv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman, Charles G Drake

Lancet Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cytokine Meteorin-like inhibits anti-tumor CD8 T cell responses by disrupting mitochondrial function.
Christopher M Jackson, Ayush Pant, Wikum Dinalankara, John Choi, Aanchal Jain, Charles G Drake

Immunity· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance.
Yu-Hwa Huang, Charles H Yoon, Amit Gandhi, Thomas Hanley, Carlos Castrillon, Charles G Drake

Commun Med (Lond)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion.
Giuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, Xiao Chen, Tessa M Firestone, Charles G Drake

Cell· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
Nirmish Singla, Thomas R Nirschl, Aleksandar Z Obradovic, Eugene Shenderov, Kara Lombardo, Charles G Drake

Sci Rep· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.
Hannah E Bergom, Laura A Sena, Abderrahman Day, Benjamin Miller, Carly D Miller, Charles G Drake

NPJ Genom Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
Jessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, Emerson A Lim, Karie Runcie, Charles G Drake

Cancer Cell· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.
Casey R Ager, Mingxuan Zhang, Matthew Chaimowitz, Shruti Bansal, Somnath Tagore, Charles G Drake

J Immunother Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Noah M Hahn, Michael A O'Donnell, Jason A Efstathiou, Marianna Zahurak, Gary L Rosner, Charles G Drake

Eur Urol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38].
Christina Guo, Ines Figueiredo, Bora Gurel, Antje Neeb, George Seed, Charles G Drake

Eur Urol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators.
Aleksandar Obradovic, Casey Ager, Mikko Turunen, Thomas Nirschl, Mohsen Khosravi-Maharlooei, Charles G Drake

Cancer Cell· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.
Eugene Shenderov, Angelo M De Marzo, Tamara L Lotan, Hao Wang, Sin Chan, Charles G Drake

Nat Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Christina Guo, Ines Figueiredo, Bora Gurel, Antje Neeb, George Seed, Charles G Drake

Eur Urol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).
Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, Fei Duan, Sreyashi Basu, Charles G Drake

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.
Casey R Ager, Mingxuan Zhang, Matthew Chaimowitz, Shruti Bansal, Aleksandar Obradovic, Charles G Drake

bioRxiv· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Emerson A Lim, Johanna C Bendell, Gerald S Falchook, Todd M Bauer, Charles G Drake

Clin Cancer Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
Christine D Palmer, Amy R Rappaport, Matthew J Davis, Meghan G Hart, Ciaran D Scallan, Charles G Drake

Nat Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis